Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Imagin Medical Inc. (IMEXF)

Add IMEXF Price Alert      Hide Sticky   Hide Intro
Moderator: jb1965
Search This Board: 
Last Post: 10/21/2017 11:12:51 AM - Followers: 8 - Board type: Free - Posts Today: 0




 Imagin Medical is a medical imaging company
Imagin Medical will establish a new standard of care in the detection and removal of cancer using endoscopes by commercializing an advanced, proprietary and patented imaging technology
 Initially targeting bladder cancer 
 Thereafter expanding to all minimally invasive surgical (MIS) procedures where endoscopes are used

Benefits of Minimally Invasive Surgery (MIS)

• Performed using tiny holes or incisions (less muscle cut)
• Reduced pain, smaller / no scarring
• Quicker recovery, shorter hospital stay, less expensive
• Minimally invasive surgeries performed using endoscopes


Endoscopic Primer

• Endoscopic means “to look inside”
• Endoscope – a medical device with attached light used to look inside organs
• Endoscopy performed when other tools, such as an MRI, X-ray, or CT scan, are inappropriate
• Endoscopies commonly performed to diagnose cancer, take tissue samples for biopsies, and to remove cancer
• Different medical specialties use different types of endoscopes
• Cystoscopes, Bronchoscopes, Gastroscopes, Laparoscopes


Endoscopic Market
 $46B growing global endoscopy market
 $1B is spent annually in US alone on bladder cancer surveillance
 Bladder cancer is 3rd most common in men and 6th most common in US overall with recurrence rate of 40 – 70% making it the most expensive cancer to treat over the lifetime of a patient
 4 million estimated urology endoscopy procedures performed each year targeting bladder cancer
 Imagin’s disruptive imaging technology squarely addresses limitations in:
• Endoscopies targeting bladder cancer (cystoscopies)
• Endoscopies targeting many other cancers



Endoscope Limitations - White Light

• Current endoscopes use “white light” (or visible light) that has been the gold standard for decades
• Highly effective for detecting protruding cancerous tumors
• Limitations of white light:
• Tumors that are flat may look the same as normal tissue
• Not effective in visualizing the edges of the tumor
• Inability to illuminate tumors beneath skin surface


Endoscope Limitations - Blue Light

• Blue light cystoscopes (white light with blue filter) used with contrasting agents induce fluorescence and improve ability to detect flat cancers and visualize edges
• Drawbacks of existing blue light technology:
• Requires one hour for the agent to be absorbed by bladder
• Surgeon must manually “switch” between white light and blue light to see tumor area
• Repeated usage of imaging agent causes adverse side-effects (FDA limits use of contrast agents to one-time use per patient)

Disruptive Technology - Endoscopes with i/Blue Imaging System

• Significantly reduced prep time with bladder absorption in less than 15 minutes vs. one hour
• Optics 100,000 X more sensitive
• Simultaneous acquisition of differing images
• No switching back and forth
• Blends the white light and fluorescence images into one
• Enables the surgeon to better visualize and resect the cancer
• This advancement makes i/Blue technology practical, not only for the O.R. but also potentially for the physicians’ office
• Adapts seamlessly to most types of endoscopes on the market
Future Development - i/Vision Imaging System

• Incorporates multiple illumination sources in one system
• Accommodates the most commonly used fluorescing contrast agents, i.e., such as those based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG)
• This instrument enables expansion into multiple endoscopic procedures such as laparoscopic (general and gynecology), colorectal, thoracic and gastroenterology procedures related to cancer and non-cancerous conditions
• Like i/Blue, blends two images into one, adapts to most endoscopes, and orders of magnitude more sensitive
Future Development - i/Red Imaging System

• Requires no contrasting agents - uses the fluorescence produced by the body and tumor itself
• Contrast between normal and cancer tissue is potentially related to difference in porphyrin content within the cells
• Dramatically expands the market to endoscopic procedures where imaging agents cannot be practically administered
• Like i/Blue, blends two images into one, adapts to most endoscopes, orders of magnitude more sensitive
Intellectual Property

• Underpinning company’s technology are three issued patents and two pending patent applications on technology related to near-infrared spectroscopic imaging for cancer and other medical applications obtained, under exclusive license, from Lawrence Livermore National Security, LLC
• Aim of licensing agreement is to commercialize the technology invented by Dr. Stavros Demos, a key advisor to the company

Product Development Roadmap

Why Invest in Imagin Medical?

• Key investment risks removed, high investment return potential
• Disruptive cutting edge imaging technology will dramatically reduce bladder cancer recurrence rates addressing $1B growing global market
• Limited R&D risks as concept is proven – this is an execution play
• Experienced medical device management team that has done it before
• Management in medical device field for over 30 years
• Worked together in previous companies
• High-margin product with strong clinical and economic advantages
• Commercial launch expected in 2018 with positive operating cash flows
• Strong acquisition market
• Most medical device companies grow by acquisition, not organically
• Company expected to have significant value with multiple liquidity options

Number of Shares Outstanding as at August 31, 2017:                50,068,739
Shares Subject to Resale Restrictions    
1) Shares subject to escrow (1,725,000 released every 6 months - Feb 9 & Aug 9) 5,175,000  
2) Performance shares 5,000,000  
Total Shares Subject to Resale Restrictions   10,175,000
Total Tradeable Float   39,893,739
Total Shares Outstanding   50,068,739

Number of Warrants Outstanding as at August 31, 2017:             25,005,064
Warrants Outstanding    
Feb 2016 Private Placement Strike @ 0.35 - expire Feb 9, 2018 7,007,413
Q4/2016 PP - Tranche 1 Strike @ 0.12 / 0.16 - expire Oct 20, 2018 5,111,300
Q4/2016 PP - Tranche 2 Strike @ 0.12 / 0.16 - expire Dec 9, 2018 3,980,565
Warrants from BSS acquisition Strike @ 0.15 - expire Feb 9, 2019 8,905,786
Total Warrants Outstanding   25,005,064

Number of Options Outstanding as at August 31, 2017:                3,350,000
 Management Options Outstanding    
Tranche 1 Strike @ 0.15 3,350,000
Total Options Outstanding   3,350,000
Various Company Links

Company Web Site
Corporate Presentation (10/2/2017)

CSE Web Site for Imagin Medical
SEDAR Web Site for Imagin Medical

Listing Statement CSE - February 16, 2016

Share Issuance - February 9, 2016
Share Issuance - August 22, 2016
Share Issuance - October 21, 2016
Share Issuance - December 13, 2016
Convertible Debt Issuance - March 3, 2017
Share Issuance - October 4, 2017

Option Grant - June 30, 2016
Option Grant - December 19, 2016
Option Grant - April 10, 2017

Information Circular - October 31, 2016

Monthly CSE Filings (CSE Form 7)
  2016 2017
January N/A Link
February Link Link
March Link Link
April Link Link
May Link Link
June Link Link
July Link Link
August Link Link
September Link  
October Link  
November Link  
December Link  

Financial Statements (FS) & Management Discussion and Analyses (MD&A)
      2015 2016 2017
Q2 Quarter Ended March 31 FS   Link Link
MD&A   Link Link
Q3 Quarter Ended June 30 FS   Link Link
MD&A   Link Link
Q4 Quarter Ended September 30 FS Link Link  
MD&A Link Link  
Q1 Quarter Ended December 31 FS Link Link  
MD&A Link Link  


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#297   Technical Spoiler Alert: The shadow in the background AMG 10/20/17 11:02:55 AM
#289   Nice! AMG 10/19/17 11:03:30 PM
#288   Have we ever seen a private placement close SO75 10/19/17 08:55:51 PM
#287   Im with you on this. The technology is SO75 10/19/17 08:30:29 PM
#286   What's his share count after the public purchase? SO75 10/19/17 08:19:11 PM
#285   Me thinks I need more shares.... ILuvblo2 10/19/17 08:17:45 PM
#283   Whoever filed could have made a mistake with teq0904 10/19/17 08:06:08 PM
#282   He sold 500,000 shares @ .06 = $30000 CAD AMG 10/19/17 07:27:47 PM
#281   My desktop couldn't pick up the name because teq0904 10/19/17 07:11:12 PM
#280   Had you clicked on the pic in the AMG 10/19/17 02:25:24 PM
#279 teq0904 10/19/17 01:24:23 PM
#278   News! Imagin releases i/Blue imaging trial patient criteria lithiumjr 10/19/17 11:55:21 AM
#277   Ired would open up the esophageal and colon teq0904 10/18/17 02:50:25 PM
#273   You are mixing up your gripes and trying teq0904 10/17/17 12:42:35 PM
#272   What does your snarky comment about the 5 teq0904 10/17/17 12:32:14 PM
#271   Jim did sell at 0.06 And did buy SO75 10/17/17 10:09:30 AM
#269   Like mgmt has nothing to do except talk teq0904 10/16/17 11:02:59 PM
#268   Mainly illegible so who is it? I wonder teq0904 10/16/17 10:44:40 PM
#267   And we have Insider buying today @15 and lithiumjr 10/16/17 09:42:31 PM
#266   I encourage all share holders to call mgt. SO75 10/16/17 09:34:04 PM
#265   Hutchins is the CEO. Has over 3.5million 7Card 10/16/17 08:49:55 PM
#264   Edward J. Hutchens Acquires 125,000 Shares of Imagin Neverending 10/16/17 06:39:38 PM
#263   We need to wake up the US market. SO75 10/16/17 02:18:05 PM
#262   $IMEXF lithiumjr 10/16/17 01:49:04 PM
#261   Who wants to be a millionaire SO75 10/16/17 11:29:25 AM
#260   Fantastic article on Imagin Medical. A must read. 7Card 10/16/17 11:03:30 AM
#259   New 52 week High on the Canadian market, lithiumjr 10/16/17 10:02:33 AM
#258   Depends on how fast the studies and improvements teq0904 10/14/17 11:47:07 PM
#257   In.3-5 months.when.the stock.will.drop until then as I Neverending 10/14/17 08:25:57 PM
#256   "there is no news expected for a while" So SO75 10/14/17 08:18:34 PM
#255   The stock.just.doubled.on the PRs.and.momentum players.It is going.down from.her Neverending 10/14/17 07:24:55 PM
#254   He has no reading comprehension so it is teq0904 10/14/17 02:51:29 PM
#253   He was being sarcastic. Meaning that it doesn't SO75 10/14/17 12:03:19 PM
#252   You must have missed the quote from the teq0904 10/14/17 11:41:31 AM
#251   Imagin is not a non-profit. Therefore, it's always AMG 10/14/17 11:12:43 AM
#250   You likely got the post of the year teq0904 10/14/17 01:48:38 AM
#249   I've been investing for decades and a buyout teq0904 10/14/17 01:16:52 AM
#248   By the time the company gets to ired, SO75 10/13/17 10:32:00 PM
#247   He says iblue will be the standard of teq0904 10/13/17 09:32:21 PM
#246   News will carry this to .30 short term SO75 10/13/17 07:48:47 PM
#245   Stock.had.a.nice. run on.the worth buying.once it sett Neverending 10/13/17 07:41:41 PM
#244   Financing closed They went for $600,000 and got SO75 10/13/17 12:23:52 PM
#243   $IMEXF PP closed !! lithiumjr 10/13/17 12:23:06 PM
#242   This is going wayyy higher guys. PP closes lithiumjr 10/11/17 05:57:00 PM
#241   He did buy at that price. That was SO75 10/11/17 02:36:13 PM
#240   Roger Buckley has already tripled his money if 7Card 10/11/17 02:34:34 PM
#239   Roger Buckley 3,5000,000 bought in the PP. SO75 10/11/17 01:54:18 PM
#238   Lith, thanks for posting that. It confirms exactly 7Card 10/11/17 01:33:37 PM
#237   IMEXF Great News ! lithiumjr 10/11/17 12:42:00 PM
#236   IMEXF is only 6 million market cap. lithiumjr 10/10/17 11:16:32 PM